Immunocore Holdings plc Revenue
Immunocore Holdings plc (IMCR) reported Revenue of $80.25 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2024-11-06
- Immunocore Holdings plc revenues for the quarter ending 2024-09-30 was $80.25M, a 23.74% increase year-over-year.
- Immunocore Holdings plc revenues for the quarter ending 2024-06-30 was $75.40M, a 26.18% increase year-over-year.
- Immunocore Holdings plc revenues for the quarter ending 2024-03-31 was $70.50M, a 28.99% increase year-over-year.
- Immunocore Holdings plc revenues for the quarter ending 2023-12-31 was $70.16M.
- Immunocore Holdings plc revenues for fiscal 2023 was $249.43M, a 43.05% increase from fiscal 2022.
- Immunocore Holdings plc revenues for fiscal 2022 was $174.36M, a 377.91% increase from fiscal 2021.
- Immunocore Holdings plc revenues for fiscal 2021 was $36.48M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2024-09-30 | $80.25M 10-Q · filed 2024-11-06 | $155.65M derived: sum of 2 quarters · filed 2024-11-06 | $226.15M 10-Q · filed 2024-11-06 | $296.31M derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | $75.40M 10-Q · filed 2024-08-08 | $145.90M 10-Q · filed 2024-08-08 | $216.06M derived: sum of 3 quarters · filed 2024-08-08 | $280.91M derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-03-31 | $70.50M 10-Q · filed 2024-05-08 | $140.66M derived: sum of 2 quarters · filed 2024-05-08 | $205.51M derived: sum of 3 quarters · filed 2024-11-06 | $265.27M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-12-31 | $70.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $135.01M derived: sum of 2 quarters · filed 2024-11-06 | $194.77M derived: sum of 3 quarters · filed 2024-11-06 | $249.43M 10-K · filed 2024-02-28 |
| 2023-09-30 | $64.85M 10-Q · filed 2024-11-06 | $124.61M derived: sum of 2 quarters · filed 2024-11-06 | $179.27M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $59.76M 10-Q · filed 2024-08-08 | $114.42M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $54.66M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $174.36M 10-K · filed 2024-02-28 | |||
| 2021-12-31 | $36.48M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |